Frequency of AQP4 and MOG Antibodies in Patients With Optic Neuritis Fulfilling Minimal New Multiple Sclerosis MRI Criteria
Authors:
- Romain DeschampsRDRomain Deschamps
- Caroline PapeixCPCaroline Papeix
- Sarah DemortiereSDSarah Demortiere
- Marine Boudot De La MotteMMMarine Boudot De La Motte
- Julie PiqueJPJulie Pique
- Clemence BoutiereCBClemence Boutiere
- Adil MaaroufAMAdil Maarouf
- Caroline Froment TiliketeCTCaroline Froment Tilikete
- Romain MarignierRMRomain Marignier
- 14 April 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (7) , e214753
Abstract
Recent revisions to multiple sclerosis (MS) diagnostic criteria include the optic nerve as a site of dissemination in space, enabling this diagnosis in patients with acute optic neuritis (ON) and a single additional MS-typical location on MRI if dissemination in time (DIT) is demonstrated. We aimed to assess the frequency of non-MS diagnoses in this context. We retrospectively analyzed consecutive patients with inaugural acute ON and at least 1 MS-typical lesion in a single brain location on baseline MRI across 3 French centers. All patients met DIT criteria and underwent aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) antibody testing. Final diagnoses were based on clinical, radiologic, and follow-up data. Among 96 patients (mean age 35.8 years; 70.8% female), 73 (76.0%) were diagnosed with MS and 23 (24.0%) with MOG antibody-associated disease (n = 18) or neuromyelitis optica spectrum disorder. Longitudinally extensive lesions, bilateral involvement, chiasmal enhancement, or optic perineuritis were observed in 100% of non-MS patients and 24.6% of patients with MS (difference 75.4%, 95% CI: 64.3-86.6; p < 0.001). All patients without these patterns were ultimately diagnosed with MS. AQP4 and MOG antibody testing, along with careful orbital MRI interpretation, is recommended in patients with ON meeting minimal new MS criteria.Keywords
This publication has 15 references indexed in Scilit:
- Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteriaThe Lancet Neurology, 2025
- One-year risk of multiple sclerosis after a first episode of optic neuritis according to modern diagnosis criteriaMultiple Sclerosis and Related Disorders, 2024
- Diagnostic criteria for optic neuritis in the acute and subacute phase: clinical uses and limitationsJournal of Neurology, 2024
- Acute optic neuritis: What are the clues to the aetiological diagnosis in real life?Multiple Sclerosis and Related Disorders, 2023
- Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteriaThe Lancet Neurology, 2023
- Time to steroids impacts visual outcome of optic neuritis in MOGADJournal of Neurology, Neurosurgery & Psychiatry, 2022
- Diagnosis and classification of optic neuritisThe Lancet Neurology, 2022
- Myelin-oligodendrocyte glycoprotein antibody-associated diseaseThe Lancet Neurology, 2021
- Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein AntibodiesAmerican Journal of Ophthalmology, 2020
- Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disordersJournal of Neurology, Neurosurgery & Psychiatry, 2017